MeFirst: A Tailored Intervention to HPV Vaccine Decision Making
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Human Papillomavirus-Related Carcinoma
- Sponsor
- University of Michigan
- Enrollment
- 661
- Locations
- 1
- Primary Endpoint
- Determine the effect of the MeFirst tool, a tailored, online HPV vaccination decision-making guide, on HPV vaccination intention and/or uptake.
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
This study will test whether a tailored, online educational intervention increases HPV vaccine uptake and intent among female college students.
Detailed Description
MeFirst is the first web-based, online, educational tool designed to promote Human Papillomavirus (HPV) vaccine awareness and understanding in an effort to improve HPV vaccine intent and uptake among female university students. HPV is the most common sexually transmitted infection and causes genital warts and cancer. The HPV vaccine has been recommended for girls ages 11-26 since 2006, yet vaccination rates remain low. Tailored online interventions may be more effective tools to promote behavior change among college students than traditional static interventions. The proposed study is a randomized controlled trial testing the efficacy of the MeFirst tool vs. standard static educational material on increasing HPV vaccination intent and uptake among female university students aged 18-26.
Investigators
Vanessa K. Dalton
Associate Professor
University of Michigan
Eligibility Criteria
Inclusion Criteria
- •enrolled at the University of Michigan
Exclusion Criteria
- •receipt of any doses of HPV vaccine
Outcomes
Primary Outcomes
Determine the effect of the MeFirst tool, a tailored, online HPV vaccination decision-making guide, on HPV vaccination intention and/or uptake.
Time Frame: Immediately post intervention, 3 months and 12 months
Intention will be assessed on a five-point scale immediately after and at 3 and 12 months. Uptake will be assessed by yes/no/don't know response to the statement, "I have received at least 1 dose of the HPV vaccine" at 3 and 12 months.
Secondary Outcomes
- Determine the effect of the MeFirst tool on HPV-related knowledge.(Immediately post intervention, 3 months and 12 months)